ELUT Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -11.53% compared to Elutia, Inc.'s net margin of -12425.36%. Elutia, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Elutia, Inc. has a consensus price target of $3.50, signalling upside risk potential of 328.14%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 428.23%. Given that Perspective Therapeutics, Inc. has higher upside potential than Elutia, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Elutia, Inc..

Elutia, Inc. has a beta of 0.618, which suggesting that the stock is 38.24% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Elutia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elutia, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Elutia, Inc. quarterly revenues are $3.3M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Elutia, Inc.'s net income of -$383K is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Elutia, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elutia, Inc. is 1.66x versus 157.98x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -11.53% compared to Elutia, Inc.'s net margin of 6.19%. Elutia, Inc.'s return on equity of -- beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Elutia, Inc. has a consensus price target of $3.50, signalling upside risk potential of 328.14%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 61.73%. Given that Elutia, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Elutia, Inc. is more attractive than InfuSystem Holdings, Inc..

Elutia, Inc. has a beta of 0.618, which suggesting that the stock is 38.24% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Elutia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elutia, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Elutia, Inc. quarterly revenues are $3.3M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Elutia, Inc.'s net income of -$383K is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Elutia, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elutia, Inc. is 1.66x versus 1.32x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex, Inc. has a net margin of -11.53% compared to Elutia, Inc.'s net margin of -44.78%. Elutia, Inc.'s return on equity of -- beat Teleflex, Inc.'s return on equity of -7.84%.

Elutia, Inc. has a consensus price target of $3.50, signalling upside risk potential of 328.14%. On the other hand Teleflex, Inc. has an analysts' consensus of $131.29 which suggests that it could grow by 27.46%. Given that Elutia, Inc. has higher upside potential than Teleflex, Inc., analysts believe Elutia, Inc. is more attractive than Teleflex, Inc..

Elutia, Inc. has a beta of 0.618, which suggesting that the stock is 38.24% less volatile than S&P 500. In comparison Teleflex, Inc. has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.113%.

Elutia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex, Inc. offers a yield of 1.32% to investors and pays a quarterly dividend of $0.34 per share. Elutia, Inc. pays -- of its earnings as a dividend. Teleflex, Inc. pays out 91.92% of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elutia, Inc. quarterly revenues are $3.3M, which are smaller than Teleflex, Inc. quarterly revenues of $913M. Elutia, Inc.'s net income of -$383K is higher than Teleflex, Inc.'s net income of -$408.9M. Notably, Elutia, Inc.'s price-to-earnings ratio is -- while Teleflex, Inc.'s PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elutia, Inc. is 1.66x versus 1.46x for Teleflex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -11.53% compared to Elutia, Inc.'s net margin of 3.93%. Elutia, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Elutia, Inc. has a consensus price target of $3.50, signalling upside risk potential of 328.14%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 125.56%. Given that Elutia, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Elutia, Inc. is more attractive than Xtant Medical Holdings, Inc..

Elutia, Inc. has a beta of 0.618, which suggesting that the stock is 38.24% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Elutia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elutia, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Elutia, Inc. quarterly revenues are $3.3M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Elutia, Inc.'s net income of -$383K is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Elutia, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 65.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elutia, Inc. is 1.66x versus 0.73x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.